VC Investment Surges In Q2 As Financial Market Recovery Momentum Builds

Anecdotal Evidence Of Improvement Backed By Data

Even after removing Xaira’s unusual $1bn seed financing, Evaluate’s data show that biopharma venture capital fundraising increased from the first to the second quarter and from Q2 of last year.

venture capital funding. green papaka, text on page wooden background. — VC funding rose across categories in the second quarter • Source: Shutterstock

Venture capital investment in the biopharmaceutical industry is on an undeniable upswing, with two quarters in a row of fundraising in 2024 that outpace the activity seen in 2023, according to data from Evaluate Pharma. In Q2, 143 companies raised $8.08bn, up from Q1 when 132 raised $6.53bn.

The first quarter of 2024 also represented a big boost, with the highest dollar amount of biopharma venture capital raised since Q2 of 2022. (Also see "Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate" - Scrip, 12 April, 2024.) The two-quarter trend seems to confirm commentary this year – first at the J.P. Morgan Healthcare Conference in January and then at the BIO International Convention in June – that while fundraising remains constrained relative to the boom years of 2020 and 2021, financial market conditions are improving

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

06 May 2025

• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

05 May 2025

• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

Finance Watch: Biohaven Gains Up To $600m In Fresh Capital

02 May 2025

• By Mandy Jackson

Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.